Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Public ClinicalTrials.gov record NCT01760005. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Study identification
- NCT ID
- NCT01760005
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Washington University School of Medicine
- Other
- Enrollment
- 490 participants
Conditions and interventions
Interventions
- E2814 Drug
- Gantenerumab Drug
- Lecanemab Drug
- Matching Placebo (E2814) Drug
- Matching Placebo (Gantenerumab) Drug
- Matching Placebo (Solanezumab) Drug
- Solanezumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2012
- Primary completion
- Mar 31, 2028
- Completion
- Jun 30, 2028
- Last update posted
- Feb 12, 2026
2012 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama in Birmingham | Birmingham | Alabama | 35294 | — |
| University of California San Diego Medical Center | La Jolla | California | 92037 | — |
| USC Keck School of Medicine | Los Angeles | California | 90033 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06510 | — |
| Emory University | Atlanta | Georgia | 30329 | — |
| Advocate Lutheran General Hospital | Park Ridge | Illinois | 60068 | — |
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | — |
| Washington University in St. Louis | St Louis | Missouri | 63110 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| Butler Hospital | Providence | Rhode Island | 02096 | — |
| Kerwin Medical Center | Dallas | Texas | 75231 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01760005, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01760005 live on ClinicalTrials.gov.